MENU

ACE-engineered iPSC-derived neutrophils: MDR infection defense

bioRxiv
Overview
Researchers have engineered human induced pluripotent stem cells (iPSCs) to express angiotensin-converting enzyme (ACE), creating neutrophils with enhanced antimicrobial capabilities. These ACE-iNeu cells demonstrated superior bactericidal activity against multidrug-resistant bacteria and reduced bacterial burdens in neutropenic mice.
In Depth

Key Findings

ACE-engineered human iPSC-derived neutrophils (ACE-iNeu) significantly enhance host defense against multidrug-resistant (MDR) bacterial infections. Specifically, these engineered cells exhibited increased bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. In vivo testing via adoptive transfer into neutropenic mice showed that ACE-iNeu significantly reduced bacterial burdens in both circulating blood and tissues.

Technical Details

The researchers engineered human iPSCs to express angiotensin-converting enzyme (ACE) using either constitutive or inducible expression methods. The resulting ACE-iNeu cells showed improvements across several functional markers:

  • Enhanced granulocytic maturation
  • Increased reactive oxygen species (ROS) generation
  • Higher inflammatory cytokine production
  • Strengthened antimicrobial signaling

To understand the underlying mechanisms, the team performed integrated metabolomic and transcriptomic analyses. These results revealed that ACE expression is associated with alterations in adenine nucleotide abundance, as well as changes in developmental and inflammatory pathways.

Background & Context

Severe neutropenia leaves patients highly susceptible to life-threatening infections. While granulocyte transfusions are a current treatment option, they are limited by the availability of donors and the variable quality of the cells provided. This study explores the use of iPSC technology to create a standardized, engineered cell source to overcome these limitations.

Significance & Outlook

The study establishes ACE engineering as a viable strategy to improve both the production efficiency and the antimicrobial potency of human iPSC-derived neutrophils. These findings provide a foundation for the further preclinical development of engineered granulocyte therapies designed to treat severe drug-resistant infections.

Source: https://doi.org/10.64898/2026.11.09.765250

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC